Fundz
Real-time · AI · Cross-signal

BioMarin Pharmaceutical just made a move. Here's exactly what to do next.

Who to reach, what to say, and why now — on BioMarin Pharmaceutical, plus every M&A move, funding round, and exec hire that follows. Verified, ICP-ranked contacts on demand (email + mobile).

Used by professionals at BlackRock, Oracle, Kleiner Perkins, HubSpot, and other leading firms — built on 10 years of proprietary signal data.

Choose your planRequest a demo

Everyone else gives you a piece

✕Crunchbase & PitchBook list the company — No person, no timing, no opener.
✕ZoomInfo & Apollo sell you a contact — No trigger, no reason to reach out now.
✕LinkedIn Sales Navigator shows you people — No real-time signal, no opener.
✕Clay enriches lists you built — No live signal of its own, no who or when.
✕ChatGPT & gen-AI tools answer on a delay — No live data, no verified contact.
Who to contactWhat to sayWhen to reach outWhy now

Only Fundz delivers all four.

BioMarin acquires Amicus Therapeutics for $4.8 billion

PUBLIC · BMRNMay 08, 2026•24 days ago

Acquiring Company

BioMarin Pharmaceutical

Acquired Company

Amicus Therapeutics

San RafaelPhiladelphiaBiotechnologyBiotechnologyHealth CareTherapeutics

Description

BioMarin Pharmaceutical Inc. has completed its acquisition of Amicus Therapeutics for $4.8 billion. This acquisition adds several important treatments for rare genetic disorders to BioMarin's portfolio. CEO Alexander Hardy noted that the acquisition supports the company's growth in revenue and expands their capabilities in enzyme therapy.

Company Information

Company

BioMarin Pharmaceutical

Location

San Rafael, California, United States

About

BioMarin is a global biotechnology company dedicated to translating the promise of genetic discovery into medicines that make a profound impact on the life of each patient. The San Rafael, California-based company, founded in 1997, has a proven track record of innovation with eight commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that offer new possibilities for people living with genetically defined conditions around the world.

Related People

Choose your plan to reveal verified contacts

Choose your plan to reveal verified contacts

Predictive Intelligence
Strategic

ML-powered predictions for BioMarin Pharmaceutical's next move

Learn about Strategic plan

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed